Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat
In a double-blind, placebo-controlled resting-state fMRI study of 40 meditation practitioners, buccal DMT–harmine increased functional connectivity within the visual network and between visual and attention/salience networks, whereas meditation with placebo produced greater network segregation. No prolonged disruption of cortical gradients was observed, indicating a return to typical brain organisation shortly after the experience and pointing to distinct neural mechanisms — and potential clinical complementarities — between meditation and psychedelic-augmented meditation.
Authors
- Erich Seifritz
- Milan Scheidegger
- Daniel Meling
Published
Abstract
Both meditation and psychedelics are widely studied for their therapeutic potential in mental health. Recent research suggests potential synergies between mindfulness practice and psychedelics, though empirical studies have primarily focused on psilocybin. This study investigates the distinct and combined effects of mindfulness practice and an ayahuasca-inspired formulation containing N,N-dimethyltryptamine (DMT) and harmine on brain functional connectivity (FC), with implications for advancing clinical interventions. In this double-blind, placebo-controlled pharmaco-functional magnetic resonance imaging (fMRI) study, 40 meditation practitioners participated in a 3-day meditation retreat. They were randomized to receive either placebo or buccal DMT–harmine (120 mg each) and underwent fMRI scans 2 days before and after administration. Neural changes were assessed using multiple connectivity metrics, including within- and between-network connectivity, network and global connectivity, and cortical gradient analyses. Within-group changes showed that meditators in the placebo group exhibited increased network segregation across several resting-state networks, while the DMT–harmine group showed increased FC within the visual network (VIS) and between VIS and attention networks. Between-group differences similarly showed increased FC between VIS and the salience network (SAL) in the DMT–harmine group compared with placebo post-retreat. No evidence of prolonged cortical gradient disruption, which is characteristic of acute psychedelic action, was observed. This suggests a return to typical brain organization shortly after the experience. These findings reveal distinct neural mechanisms underlying meditation and psychedelic-augmented meditation. While meditation alone reduced FC between networks, DMT–harmine increased within- and between-network connectivity. Given the potential of meditation and psychedelics for improving mental health, further exploration of their synergistic potential in clinical contexts is warranted. This study advances the understanding of how psychedelics and mindfulness practice shape brain function, offering insights into their complementary roles in emotional and psychological well-being.
Research Summary of 'Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat'
Introduction
Serotonergic psychedelics such as psilocybin, LSD and N,N-dimethyltryptamine (DMT) produce profound alterations of consciousness largely via 5-HT2A receptor agonism. Ayahuasca combines DMT with the monoamine‑oxidase inhibitor harmine to permit oral activity and has been investigated for therapeutic effects in depression, PTSD and addiction. Parallel lines of research have shown that meditation practices also alter consciousness and can change brain functional connectivity (FC), with reported effects on networks such as the visual network (VIS), salience network (SAL), default mode network (DMN) and frontoparietal network (FPN). Prior fMRI work has examined acute and subacute connectivity changes after psychedelics and after meditation, and a small number of studies have begun to probe combined psychedelic‑meditation interventions, chiefly with psilocybin, but it remains unclear whether findings generalise across compounds or how DMT‑based formulations interact with meditation practice. Egger and colleagues designed the present study to test whether an ayahuasca‑inspired formulation (oromucosal DMT plus harmine) administered during a 3‑day meditation retreat would produce distinct or synergistic subacute changes in resting‑state FC compared with placebo. The investigators focused on four complementary connectivity domains: within‑ and between‑network FC of major resting‑state networks, network‑to‑whole‑brain connectivity (voxel-wise FC), parcel‑wise global connectivity, and cortical gradient structure and dispersion. Based on earlier subacute and acute psychedelic studies, they hypothesised increased within‑SAL FC and altered DMN integrity, plus greater VIS‑DMN and SAL‑DMN coupling and higher global FC in the DMT‑harmine group versus placebo, and they tested whether cortical gradient perturbations persisted two days after administration.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compounds
- Topics
- Authors
- APA Citation
Egger, K., Meling, D., Polat, F., Seifritz, E., Avram, M., & Scheidegger, M. (2025). Meditation, psychedelics, and brain connectivity: A randomized controlled resting-state fMRI study of N,N-dimethyltryptamine and harmine in a meditation retreat. Imaging Neuroscience, 3. https://doi.org/10.1162/imag.a.907
References (37)
Papers cited by this study that are also in Blossom
Andersen, K. A. A., Carhart-Harris, R. L., Nutt, D. J. et al. · Acta Psychiatrica Scandinavica (2020)
Avram, M., Fortea, L., Wollner, L. et al. · Molecular Psychiatry (2024)
Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)
Carhart-Harris, R. L., Leech, R., Shanahan, M. et al. · Frontiers in Human Neuroscience (2014)
Daws, R. E., Timmermann, C., Giribaldi, B. et al. · Nature Medicine (2022)
De Araujo, D. B., Ribeiro, S., Cecchi, G. A. et al. · Human Brain Mapping (2011)
Domínguez-Clavé, E., Soler, J., Elices, M. et al. · Brain Research Bulletin (2016)
Dornbierer, D. A., Marten, L., Mueller, J. et al. · Frontiers in Pharmacology (2023)
Egger, K., Redondo, J. J., Müller, J. et al. · Biomedicine & Pharmacotherapy (2025)
Girn, M., Roseman, L., Bernhardt, B. et al. · NeuroImage (2022)
Show all 37 referencesShow fewer
Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Journal of Psychopharmacology (2017)
Knight, G., Rucker, J., Cleare, A. J. et al. · Frontiers in Psychiatry (2022)
Lebedev, A. V., Kaelen, M., L€ Ovd En, M. et al. · Human Brain Mapping (2016)
Lyons, T., Spriggs, M. J., Kerkelä, L. et al. · Biorxiv (2024)
Madsen, M. K., Stenbaek, D. S., Arvidsson, A. et al. · European Neuropsychopharmacology (2021)
Mallaroni, P., Mason, N. L., Kloft, L. et al. · NeuroImage (2024)
McCulloch, D. E-W., Knudsen, G. M., Barrett, F. S. et al. · Neuroscience and Biobehavioral Reviews (2022)
Meling, D., Egger, K., Aicher, H. D. et al. · Journal of Psychopharmacology (2024)
Milliere, R., Carhart-Harris, R. L., Roseman, L. et al. · Frontiers in Psychology (2018)
Rieser, N. M. · Biological Psychiatry (2024)
Müller, F., Holze, F., Becker, A. M. et al. · Psychopharmacology (2022)
Nichols, D. E. · Pharmacological Reviews (2016)
Pasquini, L., Palhano-Fontes, F., Araújo, D. B. · Journal of Psychopharmacology (2020)
Peill, J. M., Trinci, K. E., Kettner, H. et al. · Journal of Psychopharmacology (2022)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · eLife (2018)
Preller, K. H., Burt, J. B., Adkinson, B. et al. · Biological Psychiatry (2020)
Ramaekers, J. G., Mallaroni, P., Kloft, L. et al. · Journal of Cognitive Neuroscience (2023)
Riba, J., Mcilhenny, E. H., Valle, M. et al. · Drug Testing and Analysis (2012)
Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)
Sampedro, F., de la Fuente Revenga, M., Valle, M. et al. · International Journal of Neuropsychopharmacology (2017)
Nicol, G. E. · Nature (2024)
Berit, S., Meling, D., Hirsch-Hoffmann, M. et al. · Scientific Reports (2024)
Smigielski, L., Scheidegger, M., Kometer, M. et al. · NeuroImage (2019)
Thomas, G., Lucas, P., Rielle Capler, N. et al. · Current Drug Abuse Reviews (2013)
Timmermann, C., Roseman, L., Haridas, S. et al. · PNAS (2023)
Uthaug, M. V., Mason, N. L., Toennes, S. W. et al. · Psychopharmacology (2021)
Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)
Cited By (1)
Papers in Blossom that reference this study
Schlomberg, J. T. T., Meling, D., Grylka, R. et al. · Scientific Reports (2026)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.